Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Policy / Regulatory

China’s NHC Launches Trial Specifications for Clinical Decision Support Systems in Hospitals

Fineline Cube Jul 31, 2023

The National Health Commission (NHC) has issued a set of specifications for the application and...

Company Drug

Yingli Pharma’s YL-17231 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jul 31, 2023

US-based Yingli Pharma, a company dedicated to developing drugs for both the China and US...

Policy / Regulatory

NHSA Issues 2023 Guidelines: Enhancing Basic Medical Insurance and Major Illness Coverage

Fineline Cube Jul 31, 2023

The National Healthcare Security Administration (NHSA) has released the “Notice on Ensuring Basic Healthcare Security...

Company Drug

Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy

Fineline Cube Jul 28, 2023

China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...

Company Deals

ACROBiosystems Partners with OBiO Technology to Advance Cell and Gene Therapy

Fineline Cube Jul 28, 2023

ACROBiosystems Group (SHE: 301080) has announced a partnership with China-based gene therapy specialist OBiO Technology...

Company Deals

Lucence and Innovent Biologics Partner to Enhance Access to Cholangiocarcinoma Treatment in Hong Kong

Fineline Cube Jul 28, 2023

Singapore-based precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto...

Company Medical Device

Beijing Balance Medical’s Transcatheter Valve System Enters China’s Innovative Device Review

Fineline Cube Jul 28, 2023

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that its transcatheter valve...

Company Drug

Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two...

Policy / Regulatory

CDE Issues Guiding Principles for Natural History Research in Rare Disease Drug Development

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released the “Guiding Principles for Natural History Research...

Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers

Fineline Cube Jul 28, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received market approval from the...

Policy / Regulatory

CDE Launches Technical Guidelines to Emphasize Patient-Centered Drug Clinical Trials

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines that encompass...

Company Drug

Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...

Company Drug

Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278

Fineline Cube Jul 28, 2023

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...

Company Deals Policy / Regulatory

Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry

Fineline Cube Jul 28, 2023

The People’s Government of Pingshan District in Shenzhen has signed a cooperation framework agreement with...

Company Drug

CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047

Fineline Cube Jul 28, 2023

China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...

Company Deals

SanReno Therapeutics Partners with WuXi STA for Comprehensive R&D and Manufacturing Services

Fineline Cube Jul 28, 2023

Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...

Company Deals

Chongqing Zhifei Biological Partners with PT Bio Farma for Global Tuberculosis Vaccine Development

Fineline Cube Jul 28, 2023

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum...

Company Drug

BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE

Fineline Cube Jul 28, 2023

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company

Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward

Fineline Cube Jul 28, 2023

US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the...

Company

Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D

Fineline Cube Jul 28, 2023

Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership....

Posts pagination

1 … 442 443 444 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.